Search

Displaying results 6651 - 6660 of 8194 in total
  1. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed...

  2. Drug

    IP501

    go.drugbank.com/drugs/DB06450
    Experimental

    IP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis.

  3. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates.

  4. Drug

    Oremepermin alfa

    go.drugbank.com/drugs/DB27148
    Investigational

    Oremepermin alfa is a recombinant human hepatocyte growth factor (isoform 3) and glycoprotein composed of an α-chain and a β-chain.[L54006] It is produced in CHO cells.[L54006]

  5. Drug

    Regramostim

    go.drugbank.com/drugs/DB05386
    Investigational

    Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too.

  6. Drug

    CEP-1347

    go.drugbank.com/drugs/DB05403
    Investigational

    CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior to and after transplantation.

  7. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A4033] Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.

  8. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  9. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    [A32829] Interestingly, dipyrithione has been studied and shown to have cytotoxic and potent broad-spectrum antitumor activity, which suggests a potential basis for an anticancer drug development.

  10. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates